Edition:
United Kingdom

Bioanalytical Systems Inc (BASI.OQ)

BASI.OQ on NASDAQ Stock Exchange Capital Market

2.36USD
20 Aug 2019
Change (% chg)

$-0.08 (-3.28%)
Prev Close
$2.44
Open
$2.45
Day's High
$2.45
Day's Low
$2.36
Volume
1,872
Avg. Vol
3,045
52-wk High
$2.45
52-wk Low
$1.18

Summary

Name Age Since Current Position

Gregory Davis

2017 Interim Chairman of the Board

Robert Leasure

2019 President, Chief Executive Officer, Director

Jill Blumhoff

40 2016 Chief Financial Officer, Vice President - Finance

Daniel Oakley

2019 Chief Operating Officer

Michael Baim

2018 Vice President - Bioanalytical Operations

Philip Downing

45 2015 Vice President - Preclinical Services

Connie Dougherty

54 2014 Vice President - Business Development

John Sagartz

2018 Chief Strategy Officer, Director

Joseph Flynn

2019 Chief Commercial Officer

Richard Johnson

70 2012 Independent Director

R. Matthew Neff

2017 Independent Director

Wendy Perrow

57 2015 Independent Director

Biographies

Name Description

Gregory Davis

Dr. Gregory C. Davis Ph.D. is Interim Chairman of the Board of the Company. Dr. Davis is currently running his own consulting firm, which he founded in 2012, assisting companies with regulatory and control strategy and product development issues. In 2014, Greg joined Calibrium, LLC as Vice President of CMC, Regulatory, and Quality. Calibrium was developing novel biotheraputics for the treatment of diabetes. The company was sold to Novo Nordisk in late 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. One of the highlights of his Lilly career was being COO of the Xigris Product Team. Xigris was the first biotechnology product ever approved for the treatment of severe sepsis. When Greg retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs. Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. He coauthored several of the ICH guidances on registration standards for biotechnology products which are still in use today. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his Ph.D. in Analytical Chemistry from Purdue University studying under Dr. Peter Kissinger, founder of BASi.

Robert Leasure

Mr. Robert Leasure is President, Chief Executive Officer, Director of the company. Since September of 2016, Mr. Leasure has worked closely with the Company's management team and board of directors to guide operations and assist BASi in restructuring and developing a growth strategy for the Company. Mr. Leasure's experience leading the Company's turnaround, including the Company's refinancing, its acquisition of Seventh Wave Laboratories, Inc., and its execution of expansion and growth plans over the last two years, ideally positions him for the role of President and Chief Executive Officer and as a director. BASi's board believes Mr. Leasure's demonstrated successes, experience, ability to develop and work collaboratively with the management team, and his ability to create and execute upon visions for the future of the Company have been, and will continue to be, critical to growing the Company's business and creating long-term shareholder value.

Jill Blumhoff

Ms. Jill C. Blumhoff is Chief Financial Officer, Vice President - Finance of the company. She joined BASi in October 2007 as Assistant Controller and has served as Director of Finance, Tax and IT since 2013. In her role, Ms. Blumhoff has been responsible for all aspects of financial reporting and disclosure in addition to leading the Company's efforts in building the financial support structure at BASi. Before joining BASi, Ms. Blumhoff held various roles of increasing responsibility in financial reporting and analysis at Wabash National Corporation, in Lafayette, Indiana. Ms. Blumhoff began her career at Ernst & Young LLP. She earned a Bachelor of Science degree in accounting from the University of Illinois at Urbana-Champaign.

Daniel Oakley

Mr. Daniel Thomas Oakley is Chief Operating Officer of the Company. Mr. Oakley previously served as Chief Executive Officer of Seventh Wave Laboratories, LLC, a subsidiary of the Company. Mr. Oakley also served in that role from January 2018 through the Company’s acquisition of Seventh Wave Laboratories’ consulting-based contract research laboratory operations in July of 2018. From 2015 to 2017, Mr. Oakley held the position of Chief Executive Officer of DTO Associates, LLC, a private consulting company which advised companies on strategic concerns. Prior to his tenure at DTO Associates, LLC, Mr. Oakley was employed as President and Chief Operating Officer of MPI Research, Inc., a non-clinical contract research organization (now a subsidiary of Charles River Labs). There are no arrangements or understandings between Mr. Oakley and any other persons pursuant to which he was elected as an officer and Mr. Oakley has no family relationships with any other director or executive officer of the Company.

Michael Baim

Mr. Michael Baim is appointed as Vice President - Bioanalytical Operations of the company effective May 7, 2018. Before joining BASi nearly four years ago, Dr. Bourdage enjoyed a long and esteemed career in the pharmaceutical industry. Having received his Ph.D. in immunochemistry from the University of Illinois, he served in leadership positions at Covance, PharmAthene, Eli Lilly, and Pharmacia/Upjohn. In addition to authoring numerous scientific papers, Dr. Bourdage is a member of the American Society of Clinical Pathologists and the American Association of Pharmaceutical Scientists. Dr. Michael Baim is an energetic and passionate leader who brings to BASi over thirty years of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology and project design and has a proven track record of delivering significant and sustainable profitable growth across many different business segments. Dr. Baim received his B.A. degree in chemistry from Whitman College in Washington State. He then studied analytical chemistry as an American Chemical Society Analytical Research Fellow at Washington State University, where he earned his Ph.D. degree. He is currently working towards his MBA in marketing management. Dr. Baim began his career at The Procter & Gamble Company in 1984, and has since held several leadership, management and technical positions at other prominent companies including Novartis and Bristol-Myers Squibb/Mead Johnson. Most recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained, double-digit growth rate for the company.

Philip Downing

Mr. Philip A. Downing is Vice President - Preclinical Services of the company. Mr. Downing has extensive experience designing and testing pre-clinical dosing formulations and has achieved success in securing an extensive customer base for preclinical and clinical service needs. After receiving a B.A. in Chemistry and Biology from Indiana University, he worked for a clinical research facility, GFi Pharmaceuticals (now Covance Labs) as an Analytical Scientist and RSO designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies.

Connie Dougherty

Ms. Connie Dougherty is the Vice President - Business Development of the Company. Ms. Dougherty served as Area Marketing Manager - Northern New Jersey, Manhattan, and Queens for Sunoco, a Division of Energy Transfer Partners. In that role Ms. Dougherty was responsible for commercializing new business opportunities and developing strategic relationships. Previously, she was Territory Manager Downstream Business for, Exxon Company, USA/Exxon Mobil –Marketing. Ms. Dougherty also held a variety of sales leadership positions at Lehigh Gas Inc. and Sun Refining and Marketing Company. Ms. Dougherty received a Bachelor of Science degree in business from Rowan University in Glassboro, New Jersey in 1985.

John Sagartz

Dr. John E. Sagartz is Chief Strategy Officer, Director of the Company. Dr. Sagartz is an adjunct associate professor of Comparative Medicine at St. Louis University's College of Medicine and serves on the Board of Directors of the Missouri Biotechnology Association. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.

Joseph Flynn

Mr. Joe Flynn is Chief Commercial Officer of the company. Mr. Flynn has an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development. Most recently, he served as Chief Commercial Officer and Executive Vice President of Seventh Wave Laboratories. Mr. Flynn joined BASi in July of last year when BASi acquired the operations of Seventh Wave in order to provide broader solutions and greater scientific expertise to its clients. Prior to his tenure at Seventh Wave Laboratories, Mr. Flynn was a global vice president of sales and client services for multiple divisions of Covance Laboratories. Prior to Covance, he held operational roles at PPD Inc. and ABC Laboratories (now Eurofins). Mr. Flynn began his career with a BS in Biochemistry from the University of Missouri, Columbia.

Richard Johnson

Dr. Richard Allen Johnson, Ph.D., is an Independent Director of the Company. Dr. Johnson is currently an executive scientific consultant. From 1990 to 2008, he served as Founder and President of AvTech Laboratories. Prior to founding AvTech Laboratories, he served in various positions with The Upjohn Company, including Senior Research Scientist, Manager of Product Control, Manager of Quality Assurance Product Support and Director of Strategic Planning. Dr. Johnson received his Bachelor of Science in Chemistry from the Illinois Institute of Technology and his Ph.D. in Chemical Physics from Michigan State University. Dr. Johnson brings to the Board of Directors knowledge and insight on scientific matters, stemming from his extensive experience in the pharmaceutical industry.

R. Matthew Neff

Mr. R. Matthew Neff is an Independent Director of the Company. Mr. Neff is currently Of Counsel with Bingham Greenebaum Doll LLP’s Corporate and Transactional Department. From August 2013 through June 2016, Mr. Neff served as Chairman, President and Chief Executive Officer of AIT Laboratories, a national toxicology lab headquartered in Indianapolis, Indiana. Mr. Neff joined AIT Laboratories after his tenure as President and Chief Executive Officer of CHV Capital, Inc., the venture capital subsidiary of Indiana University Health, a role he had held since 2007. Mr. Neff started his career as a practicing lawyer and Partner at Baker & Daniels. He then served as the Deputy to the Chairman of the Federal Housing Finance Board (now known as the Federal Housing Finance Agency) in the first Bush Administration. Thereafter, he became the co-founder and Chief Executive Officer of two Indianapolis companies: Circle Investors, an insurance holding company then chaired by former Vice President of the United States, Dan Quayle, and Senex Financial Corp., a healthcare receivables finance company. Mr. Neff currently serves on the Board of Directors of Fairbanks Addiction Treatment Center and was a member of Riley Children’s Foundation’s Board of Directors from January 2000 to November 2012. Mr. Neff earned his bachelor’s degree and graduated a Phi Beta Kappa from DePauw University. He also received his Juris Doctor degree from Indiana University School of Law, where he was the Executive Editor of the Indiana Law Review.

Wendy Perrow

Ms. Wendy Perrow is Independent Director of the Company. Ms. Perrow is President and Chief Executive Officer at Alba Therapeutics. Ms. Perrow joined Alba Therapeutics in 2008 as Vice President, Business Development, Marketing and Alliance Management. She was appointed President and Chief Operating Officer in 2011 and named Chief Executive Officer in 2013. Prior to joining Alba Therapeutics, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc. From 1989 to 2003, Ms. Perrow held positions at Merck and Co., Inc. in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. Ms. Perrow holds a bachelor’s degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business. Through her extensive experience, Ms. Perrow brings knowledge and insight of the pharmaceutical industry as well as management expertise.